GRIFOLS S A/S (NASDAQ:GRFS) has received an average rating of “Hold” from the ten analysts that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $20.00.

Several equities research analysts have commented on the stock. BidaskClub downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Wednesday. Berenberg Bank raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a report on Thursday, October 11th. UBS Group downgraded shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a report on Wednesday, October 3rd. Zacks Investment Research downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Tuesday, October 2nd. Finally, Morgan Stanley dropped their price objective on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating on the stock in a report on Monday, October 1st.

Several institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its position in shares of GRIFOLS S A/S by 14.9% during the first quarter. PNC Financial Services Group Inc. now owns 20,428 shares of the biotechnology company’s stock valued at $433,000 after buying an additional 2,656 shares during the period. Blair William & Co. IL increased its position in shares of GRIFOLS S A/S by 9.9% during the first quarter. Blair William & Co. IL now owns 38,960 shares of the biotechnology company’s stock valued at $826,000 after buying an additional 3,499 shares during the period. Verition Fund Management LLC increased its position in shares of GRIFOLS S A/S by 23.2% during the second quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 3,539 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of GRIFOLS S A/S by 14.3% during the second quarter. BNP Paribas Arbitrage SA now owns 34,055 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 4,255 shares during the period. Finally, Great West Life Assurance Co. Can increased its position in shares of GRIFOLS S A/S by 1.1% during the second quarter. Great West Life Assurance Co. Can now owns 464,947 shares of the biotechnology company’s stock valued at $9,990,000 after buying an additional 5,238 shares during the period. Hedge funds and other institutional investors own 21.05% of the company’s stock.

NASDAQ GRFS traded down $0.82 during trading on Friday, hitting $19.35. 1,464,000 shares of the company’s stock traded hands, compared to its average volume of 880,244. The company has a market cap of $13.47 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 1.38 and a beta of 1.21. GRIFOLS S A/S has a 12-month low of $18.69 and a 12-month high of $25.18. The company has a quick ratio of 1.12, a current ratio of 2.90 and a debt-to-equity ratio of 1.52.

GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings data on Friday, July 27th. The biotechnology company reported $0.34 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.34. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.35 billion. GRIFOLS S A/S had a net margin of 16.55% and a return on equity of 18.32%. As a group, equities research analysts anticipate that GRIFOLS S A/S will post 1.21 EPS for the current year.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.